Literature DB >> 33489527

Colorectal Cancer in a Patient With Multiple Myeloma: A Treatment Dilemma.

Chung-Ting J Kou1, Joshua Romain2, Devin R Broadwater3, Taylor Barnett2.   

Abstract

Multiple myeloma (MM) is a malignancy of plasma cells characterized by the clonal proliferation of plasma cells that produce monoclonal immunoglobulins. While typically considered to be incurable, advances in treatment options have led to remarkable improvements in survival for these patients. Accumulating evidence suggests an increased risk for the development of a secondary primary malignancy (SPM) in these patients, perhaps as a result of myeloma directed therapy or as an effect of their underlying disease process. Here we present a case of a patient who was diagnosed with an SPM while undergoing palliative treatment for multiple myeloma and a treatment approach.
Copyright © 2020, Kou et al.

Entities:  

Keywords:  bisphosphonate; colon adenocarcinoma; fluoropyrimidines; multiple myeloma; secondary primary malignancy

Year:  2020        PMID: 33489527      PMCID: PMC7808961          DOI: 10.7759/cureus.12112

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  17 in total

Review 1.  Second malignancies after multiple myeloma: from 1960s to 2010s.

Authors:  Anish Thomas; Sham Mailankody; Neha Korde; Sigurdur Y Kristinsson; Ingemar Turesson; Ola Landgren
Journal:  Blood       Date:  2012-02-06       Impact factor: 22.113

2.  Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma.

Authors:  R Govindarajan; S Jagannath; J T Flick; D H Vesole; J Sawyer; B Barlogie; G Tricot
Journal:  Br J Haematol       Date:  1996-11       Impact factor: 6.998

3.  Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.

Authors:  Yuan Xiao Zhu; Esteban Braggio; Chang-Xin Shi; K Martin Kortuem; Laura A Bruins; Jessica E Schmidt; Xiu-Bao Chang; Paul Langlais; Moulun Luo; Patrick Jedlowski; Betsy LaPlant; Kristina Laumann; Rafael Fonseca; P Leif Bergsagel; Joseph Mikhael; Martha Lacy; Mia D Champion; A Keith Stewart
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

Review 4.  Advances in the biology and treatment of bone disease in multiple myeloma.

Authors:  Noopur Raje; G David Roodman
Journal:  Clin Cancer Res       Date:  2011-03-15       Impact factor: 12.531

5.  In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates.

Authors:  A Aparicio; A Gardner; Y Tu; A Savage; J Berenson; A Lichtenstein
Journal:  Leukemia       Date:  1998-02       Impact factor: 11.528

Review 6.  Second primary malignancies in multiple myeloma: an overview and IMWG consensus.

Authors:  P Musto; K C Anderson; M Attal; P G Richardson; A Badros; J Hou; R Comenzo; J Du; B G M Durie; J San Miguel; H Einsele; W M Chen; L Garderet; G Pietrantuono; J Hillengass; R A Kyle; P Moreau; J J Lahuerta; O Landgren; H Ludwig; A Larocca; A Mahindra; M Cavo; A Mazumder; P L McCarthy; A Nouel; S V Rajkumar; A Reiman; E Riva; O Sezer; E Terpos; I Turesson; S Usmani; B M Weiss; A Palumbo
Journal:  Ann Oncol       Date:  2017-02-01       Impact factor: 32.976

7.  Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.

Authors:  C M Shipman; M J Rogers; J F Apperley; R G Russell; P I Croucher
Journal:  Br J Haematol       Date:  1997-09       Impact factor: 6.998

8.  Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.

Authors:  Antonio Palumbo; Sara Bringhen; Shaji K Kumar; Giulia Lupparelli; Saad Usmani; Anders Waage; Alessandra Larocca; Bronno van der Holt; Pellegrino Musto; Massimo Offidani; Maria T Petrucci; Andrea Evangelista; Sonja Zweegman; Ajay K Nooka; Andrew Spencer; Meletios A Dimopoulos; Roman Hajek; Michele Cavo; Paul Richardson; Sagar Lonial; Giovannino Ciccone; Mario Boccadoro; Kenneth Anderson; Bart Barlogie; Pieter Sonneveld; Philip L McCarthy
Journal:  Lancet Oncol       Date:  2014-02-11       Impact factor: 41.316

9.  Second primary malignancies after autologous hematopoietic cell transplantation for multiple myeloma.

Authors:  Amrita Y Krishnan; Matthew Mei; Can-Lan Sun; Sandra H Thomas; Jennifer Berano Teh; Tongjun Kang; Myo Htut; George Somlo; Firoozeh Sahebi; Stephen J Forman; Smita Bhatia
Journal:  Biol Blood Marrow Transplant       Date:  2012-10-13       Impact factor: 5.742

10.  Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries.

Authors:  Tianhui Chen; Mahdi Fallah; Hermann Brenner; Lina Jansen; Elias K Mai; Felipe A Castro; Alexander Katalinic; Katharina Emrich; Bernd Holleczek; Karla Geiss; Andrea Eberle; Kristina Sundquist; Kari Hemminki
Journal:  Sci Rep       Date:  2016-02-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.